Spectrum Pharmaceuticals Inc (SPPI):企業の財務・戦略的SWOT分析

◆英語タイトル:Spectrum Pharmaceuticals Inc (SPPI) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA904C15770
◆発行会社(調査会社):GlobalData
◆発行日:2019年4月
◆ページ数:54
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥13,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥27,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥40,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Spectrum Pharmaceuticals Inc (SPPI) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Spectrum Pharmaceuticals Inc (Spectrum) is a biotechnology company that develops and commercializes a pipeline of late-stage clinical and commercial products with focus on hematology and oncology. The company’s marketed drugs include Fusilev (levoleucovorin); Folotyn (pralatrexate injection); Zevalin (ibritumomab tiuxetan); Marqibo (vincristine sulfate liposome injection), Beleodaq (belinostat) and Evomela (Captisol-Enabled Melphalan). It also has drugs in mid-to-late stage development, namely, Rolontis (eflapegrastim) for chemotherapy-induced neutropenia; Qapzola (apaziquone) for Intravesical Instillation; and Poziotinib for the treatment of various types of cancers. The company markets its products through direct sales force in the US and through distributors in Europe. Spectrum is headquartered in Henderson, Nevada, the US.

Spectrum Pharmaceuticals Inc Key Recent Developments

Mar 13,2019 Spectrum Pharmaceuticals to Present Corporate Update at the Oppenheimer 29th Annual Healthcare Conference on March 20
Feb 28,2019 Spectrum Pharmaceuticals reports fourth quarter 2018 and full year 2018 financial results and pipeline update
Jan 18,2019 Acrotech Biopharma to buy seven drugs from Spectrum for $300m
Dec 06,2018 Spectrum Pharmaceuticals Announces Results from the RECOVER Phase 3 Study of ROLONTIS (eflapegrastim) at the 2018 SABCS Annual Meeting

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Spectrum Pharmaceuticals Inc – Key Facts
Spectrum Pharmaceuticals Inc – Key Employees
Spectrum Pharmaceuticals Inc – Key Employee Biographies
Spectrum Pharmaceuticals Inc – Major Products and Services
Spectrum Pharmaceuticals Inc – History
Spectrum Pharmaceuticals Inc – Company Statement
Spectrum Pharmaceuticals Inc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture
Section 2 – Company Analysis
Company Overview
Spectrum Pharmaceuticals Inc – Business Description
Product Category: Beleodaq
Overview
Performance
Product Category: Evomela
Overview
Performance
Product Category: Folotyn
Overview
Performance
Product Category: Fusilev
Performance
Product Category: Khapzory
Overview
Performance
Product Category: Marqibo
Overview
Performance
Product Category: Zevalin
Overview
Performance
Product Category: License fees and service revenue
Performance
Product Category: Product Sales
Performance
Geographical Segment: International
Performance
Geographical Segment: Other
Performance
Geographical Segment: The US
Performance
R&D Overview
Spectrum Pharmaceuticals Inc – SWOT Analysis
SWOT Analysis – Overview
Spectrum Pharmaceuticals Inc – Strengths
Spectrum Pharmaceuticals Inc – Weaknesses
Spectrum Pharmaceuticals Inc – Opportunities
Spectrum Pharmaceuticals Inc – Threats
Spectrum Pharmaceuticals Inc – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Spectrum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Spectrum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Spectrum Pharmaceuticals Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Mar 13, 2019: Spectrum Pharmaceuticals to Present Corporate Update at the Oppenheimer 29th Annual Healthcare Conference on March 20
Feb 28, 2019: Spectrum Pharmaceuticals reports fourth quarter 2018 and full year 2018 financial results and pipeline update
Jan 18, 2019: Acrotech Biopharma to buy seven drugs from Spectrum for $300m
Dec 06, 2018: Spectrum Pharmaceuticals Announces Results from the RECOVER Phase 3 Study of ROLONTIS (eflapegrastim) at the 2018 SABCS Annual Meeting
Nov 13, 2018: Spectrum Pharmaceuticals names Dr. Jeffrey Vacirca to its Board of Directors
Nov 08, 2018: Spectrum Pharmaceuticals reports third quarter 2018 pipeline update and financial results
Nov 06, 2018: Haymi Behar to Head SPI’s International Marketing Operations
Nov 01, 2018: Spectrum Pharmaceuticals Announces Third Quarter 2018 Financial Results Teleconference and Webcast
Oct 18, 2018: Spectrum Pharmaceuticals names Dr. Francois Lebel as chief medical officer
Oct 18, 2018: Spectrum pharmaceuticals announces Dr. Francois Lebel as chief medical officer
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Spectrum Pharmaceuticals Inc, Key Facts
Spectrum Pharmaceuticals Inc, Key Employees
Spectrum Pharmaceuticals Inc, Key Employee Biographies
Spectrum Pharmaceuticals Inc, Major Products and Services
Spectrum Pharmaceuticals Inc, History
Spectrum Pharmaceuticals Inc, Other Locations
Spectrum Pharmaceuticals Inc, Subsidiaries
Spectrum Pharmaceuticals Inc, Joint Venture
Spectrum Pharmaceuticals Inc, Key Competitors
Spectrum Pharmaceuticals Inc, Ratios based on current share price
Spectrum Pharmaceuticals Inc, Annual Ratios
Spectrum Pharmaceuticals Inc, Annual Ratios (Cont...1)
Spectrum Pharmaceuticals Inc, Interim Ratios
Spectrum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Spectrum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Spectrum Pharmaceuticals Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Spectrum Pharmaceuticals Inc, Performance Chart (2014 - 2018)
Spectrum Pharmaceuticals Inc, Ratio Charts
Spectrum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Spectrum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

★海外企業調査レポート[Spectrum Pharmaceuticals Inc (SPPI):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Australasian Resources Limited (ARH):企業の財務及び戦略的SWOT分析
    Summary Australasian Resources Limited (Australasian Resources) is a mining company that offers exploration services. The company explores and develops mineral resource properties in Australia. It explores for iron, nickel and uranium ores. Australasian Resources has non-iron ore assets that include …
  • China Resources Land Limited:企業の戦略・SWOT・財務情報
    China Resources Land Limited - Strategy, SWOT and Corporate Finance Report Summary China Resources Land Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Alliqua BioMedical Inc (ALQA):製薬・医療:M&Aディール及び事業提携情報
    Summary Alliqua BioMedical Inc (Alliqua BioMedical), formerly HepaLife Technologies Inc, is a regenerative technology company that builds a suite of regenerative solutions for wound and tissue repair. The company’s products comprise ultrasound healing therapy, human biologics, antimicrobial protecti …
  • Key Petroleum Limited (KEY):企業概要、財務及び戦略的SWOT分析
    Summary Key Petroleum Limited (Key Petroleum) is an oil and gas service provider. The company develops and explores conventional and unconventional projects in Western Australia. Its projects include Canning Basin and Perth Basin. The company holds interests in six exploration permits such as EP 438 …
  • Heartland Dental Care(製薬・医療分野):企業M&A動向
    Summary Heartland Dental Care (HDC) is a dental practice management organization. The organization provides support through continuing education; and management services, such as staffing, human relations, purchasing, administration, financial, marketing and information technology support. The organ …
  • GLG Life Tech Corp (GLG):企業の財務・戦略的SWOT分析
    GLG Life Tech Corp (GLG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Akonni Biosystems, Inc.:企業のM&A・提携動向(医療機器分野)
    Summary Akonni Biosystems, Inc. (Akonni Biosystems) is a biotechnology company that develops, manufactures, and distributes integrated molecular diagnostic systems for the healthcare markets. The company offers products such as nucleic acid extraction kits, molecular diagnostic tests, thermal cycler …
  • Ora Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Ora Inc (Ora) is an ophthalmic contract research organization that provides clinical research and drug development services. The organization offers pre-clinical research, animal toxicology studies, and compounds identification and procurement services. It offers clinical study project manag …
  • CorNova, Inc.:(医療機器分野)企業M&A及び提携動向
    Summary CorNova, Inc. (CorNova) is a medical device company. The company manufactures endovascular devices for the cardiovascular markets. Its product FiberHalo SRM Stent Deployment Catheter will enable the physician to deploy a stent and measure in-stent lumen area during the angioplasty procedure. …
  • SK Networks Co., Ltd. (formerly Sunkyung Textile):企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' SK Networks Co., Ltd. (formerly …
  • Taiko Pharmaceutical Co.,Ltd. (4574):企業の財務及び戦略的SWOT分析
    Summary Taiko Pharmaceutical Co.,Ltd.(Taiko) is a pharmaceutical company that manufactures, sells and exports gastrointestinal drugs. The company operates through three business fields such as pharmaceuticals business, infection control business, and other business lines. Taiko’s products include se …
  • Karoon Gas Australia Ltd (KAR):石油・ガス:M&Aディール及び事業提携情報
    Summary Karoon Gas Australia Ltd (Karoon) is a major independent upstream oil and gas company, which explores for oil and gas and develops assets. It also operates projects in Brazil and Peru. Karoon has significant drilling opportunities in proven and prospective petroleum systems. The company focu …
  • Camel-IDS NV-製薬・医療分野:企業M&A・提携分析
    Summary Camel-IDS NV (Camel-IDS) is a biotechnology company which develops targeted radionuclide therapeutic solutions for the treatment of cancer. The company focuses on developing its lead compound radiopharmaceutical drug for treatment of Her2 positive cancer. Its technology platform is based on …
  • Brookdale Senior Living, Inc.:企業の戦略・SWOT・財務分析
    Brookdale Senior Living, Inc. - Strategy, SWOT and Corporate Finance Report Summary Brookdale Senior Living, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Program for Appropriate Technology in Health-製薬・医療分野:企業M&A・提携分析
    Summary Program for Appropriate Technology in Health (PATH) is a healthcare organization that offers vaccines, drugs, diagnostics, devices, system and service innovations, and digital health solutions. The organization offers HIV and AIDS, influenza, malaria and tuberculosis care services. It develo …
  • Apotex Inc:企業のM&A・提携動向(医療分野)
    Summary Apotex Inc (Apotex) produces and markets a wide range of generic pharmaceuticals. It also undertakes the research, development, manufacture and distribution of non-prescription and private label medicines, fine chemicals and disposable plastics for medicinal use. The company has research and …
  • Krosaki Harima Corporation (5352):企業概要・SWOT分析
    This report is a crucial resource for industry executives and anyone looking to access key information about "Krosaki Harima Corporation" The report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format. Timetric strictl …
  • The Ultimate Software Group, Inc. (ULTI):企業の財務・戦略的SWOT分析
    The Ultimate Software Group, Inc. (ULTI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Cavion LLC(製薬・医療分野):企業M&A動向
    Summary Cavion LLC (Cavion) is a clinical stage biopharmaceutical company. The company develops oncology drugs for solid tumors. Cavion’s product under clinical development includes TTL-1177 and mibefradil dihydrochloride. Mibefradil Dihydrochloride is a T-type calcium channel blocker, for the treat …
  • United Engineers Limited:企業の戦略・SWOT・財務分析
    SummaryUnited Engineers Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Ke …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆